| 引用本文：杨莹, 刘雨欣, 毛靖, 毛宗福.药品集中带量采购政策对我国医药产业的影响——基于SCP范式的综述研究[J].中国卫生政策研究,2023,16(12):40-48 |
|
| 药品集中带量采购政策对我国医药产业的影响——基于SCP范式的综述研究 |
| 投稿时间：2023-09-11 修订日期：2023-11-01 PDF全文浏览 HTML全文浏览 |
| 杨莹1, 刘雨欣2, 毛靖1, 毛宗福2,3 |
1. 华中科技大学同济医学院护理学院 湖北武汉 430030;
2. 武汉大学董辅礽经济社会发展研究院 湖北武汉 430071;
3. 武汉大学全球健康研究中心 湖北武汉 430071 |
| 摘要:目的：系统综述药品集中带量采购（以下简称“集采”）政策对我国医药产业的影响。方法：通过中国知网、万方、PubMed、Web of Science数据库检索2019年1月1日至2023年7月31日公开发表的文献。借鉴市场结构（Structure）—企业行为（Conduct）—行业绩效（Performance）分析框架（简称“SCP范式”）构建主题框架进行资料整理分析。结果：纳入41篇文献，报告市场结构、企业行为、行业绩效三个维度影响的文献分别有10篇（24.4%）、24篇（58.5%）、23篇（56.1%），共提取10个二级主题。文献表明：市场结构上，集采政策后中标企业市场份额大幅提升，行业集中度明显提高；企业行为上，中标与未中标企业研发投入均增加，企业针对集采产品的销售投入削减，但非集采产品的销售投入未见减少；行业绩效上，集采政策对经营绩效的影响因企业而异，政策初步起到促进中标企业创新产出作用。结论：集采政策在优化市场结构、引导企业行为、提升行业绩效方面具有积极作用，为巩固和扩大政策影响，建议进一步强化药品价格综合治理，拓展集采市场边界，加强政策监测与追踪研究。 |
| 关键词:集中带量采购 医药产业 系统综述 SCP范式 |
| 基金项目:国家卫生健康委委托项目 |
|
| The impact of centralized volume-based procurement policy on the pharmaceutical industry: Review based on the SCP paradigm |
| YANG Ying1, LIU Yu-xin2, MAO Jing1, MAO Zong-fu2,3 |
1. School of Nursing, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei 430030, China;
2. Dong Fureng Institute of Economic and Social Development, Wuhan University, Wuhan Hubei 430071, China;
3. Global Health Institute, Wuhan University, Wuhan Hubei 430071, China |
| Abstract:Objective: To systematically review the impact of Chinese centralized volume-based procurement (VBP) policy on the pharmaceutical industry. Methods: Relevant literature published between January 1, 2019 and July 31, 2023 were retrieved from the database of CNKI, WanFang data, PubMed, and Web of Science. A thematic analysis framework was constructed for data collation and analysis applying the Structure-Conduct-Performance (SCP) paradigm. Results: Forty-one studies were included, with 10 (24.4%), 24 (58.5%), and 23 (56.1%) reporting the dimension of structure, conduct, and performance, covering 10 secondary themes. Literature shows that, in terms of market structure, the market share of bid-winning enterprises increased after VBP policy, and the concentration ratio of pharmaceutical industry promoted; as for enterprise conduct, the R&D investment of both bid-winning and bid-non-winning enterprises increased under policy implementation, and the selling expenses on policy-covered products significantly reduced while policy-uncovered products did not; as for industry performance, the impact of VBP policy on operational performance varies among enterprise, and the initially positive effect on promoting innovative output of bid-winning enterprises was observed. Conclusions: The VBP policy has shown positive effects in optimizing market structure, guiding enterprise conduct, and improving industry performance. To consolidate and expand policy effects, it is recommended to further strengthen the comprehensive management of drug prices, expand the boundaries of the VBP market, and strengthen policy monitoring and tracking research. |
| Key words:Centralized volume-based procurement Pharmaceutical industry Systematic review SCP paradigm |
| 摘要点击次数: 1802 全文下载次数: 327 |
|
|
|
|
|
